About gemtuzuma b ozogamicin
CD33-targeted antibody-drug conjugate
Used for
- Treats newly diagnosed CD33-positive acute myeloid leukemia (AML), with chemotherapy or alone.
- Treats relapsed or refractory CD33-positive AML in adults and children aged two years or older.
Usual adult dose
Dose depends on AML treatment plan and body surface area; commonly 3 mg/m² per infusion, with regimen-specific timing and limits.
Usual dose in children
For children aged two years or older, dose depends on body surface area and treatment plan; commonly 3 mg/m² per infusion.
Common side effects
- Low blood counts and serious infections
- Bleeding
- Infusion reactions
- Liver injury, including sinusoidal obstruction syndrome
Important warnings
- Can cause severe or fatal liver injury; monitor liver function.
- Can cause life-threatening bleeding, infection, or prolonged low blood counts.
- Infusion reactions may be severe; premedication and monitoring are required.
- May harm an unborn baby; effective contraception is recommended during treatment.
Pregnancy
May cause fetal harm. Avoid pregnancy during treatment; discuss contraception and pregnancy planning with the oncology team.
Breastfeeding
Breastfeeding is not recommended during treatment and for at least one month after the last dose.
Interactions
- Other medicines that damage the liver may increase liver-injury risk.
- Medicines that prolong QT interval may increase abnormal-heart-rhythm risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.